Cargando…
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
FGFR1 amplification occurs in ~20% of sqNSCLC and trials with FGFR inhibitors have selected FGFR1 amplified patients by FISH. Lung cancer cell lines were profiled for sensitivity to AZD4547, a potent, selective inhibitor of FGFRs 1–3. Sensitivity to FGFR inhibition was associated with but not wholly...
Autores principales: | Rooney, Claire, Geh, Catherine, Williams, Victoria, Heuckmann, Johannes M., Menon, Roopika, Schneider, Petra, Al-Kadhimi, Katherine, Dymond, Michael, Smith, Neil R., Baker, Dawn, French, Tim, Smith, Paul D., Harrington, Elizabeth A., Barrett, J. Carl, Kilgour, Elaine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764357/ https://www.ncbi.nlm.nih.gov/pubmed/26905262 http://dx.doi.org/10.1371/journal.pone.0149628 |
Ejemplares similares
-
Anlotinib plus chemotherapy for T790M‐negative
EGFR
‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
por: Li, Juan, et al.
Publicado: (2022) -
Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015) -
In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites
por: Baek, Kyung-Hwa, et al.
Publicado: (2022) -
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Terp, Mikkel G., et al.
Publicado: (2021) -
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)